Bausch Health Announces 2025 Gastrointestinal Health Scholars Program Winners
LAVAL, QC / / August 7, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) and its gastroenterology (GI) business, Salix Pharmaceuticals ("Salix"), today announced the recipients of its 2025 Salix Gastrointestinal Health Scholars Program. For the sixth year, Bausch Health is proud to award 10 deserving students living with a GI disease $10,000 each to further their higher education.
"The overwhelming response to our scholarship program reflects the unwavering drive and determination of students within the GI community. These remarkable individuals refuse to let their illness define their path," said Aimee Lenar, Executive Vice President, US Pharma, Bausch Health. "Each year, we are inspired by their stories of resilience, which serve as powerful reminders of true strength. Bausch Health is proud to continue providing meaningful financial support to help ease their burden and empower their academic success."
The 2025 scholarship recipients were chosen from a competitive pool of over 370 applicants. As part of the selection process, candidates submitted personal essays detailing how their gastrointestinal condition has shaped their educational journey and highlighting the support provided by their health care providers in helping them achieve their academic and personal milestones. All applications were thoroughly evaluated by an independent panel of judges.
The program recognizes students across a wide range of educational pursuits, with scholarships in three categories, including the Undergraduate Scholar Awards, for those pursuing undergraduate degrees; the Graduate Scholar Awards, for those pursuing graduate degrees; and the Working and/or Single Parent's Scholar Award, for students who are working and/or single parents pursuing undergraduate, vocational/technical, or graduate degrees.
This year's recipients shared powerful reflections on what Bausch Health's Salix Gastrointestinal Health Scholars Award means to them and how it's helping shape their academic journey.
"Although my diagnosis has provided many challenges, it has ultimately fueled my desire to become a physician. I have found a passion for helping others, and I plan to become a pediatric gastroenterologist," said Alexis Weary, a scholarship recipient. "I truly appreciate the company for their work in gastrointestinal healthcare and for providing me with this scholarship to help me turn my dreams into a reality."
Another scholarship recipient, Samantha Smith said, "This scholarship affirms my belief that chronic illness can be a source of resilience and innovation. I'm deeply grateful to Bausch Health's Salix Gastrointestinal Health Scholars Program for empowering me to continue advocating for inclusive policy reformation."
Their words reflect the heart of the program-empowering students to pursue their goals with confidence, support, and pride.
Bausch Health's 2025 Salix Gastrointestinal Health Scholars Program recipients are:
Undergraduate Scholar Awards
Krish Desai - University of California Los Angeles (UCLA)
Maya Fischler - Brown University
Annie Jones - Colorado State University
Ethan Leicht - Louisville State University
Maggie Schaefer - Creighton University
Keaton Van Nostrand - Florida State University
Graduate Scholar Awards
Kunika Chahal - SUNY Downstate College of Medicine
Samantha Smith - Harvard Business School
Alexis Weary - Nova Southeastern University College of Osteopathic Medicine
Working and/or Single Parent's Scholar Award
Miriam McCarter - Brigham Young University Law School
To learn more about Bausch Health's Salix Gastrointestinal Health Scholars Program, visit www.salix.com/scholarship or visit www.bauschhealth.com.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global, diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb Corporation. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. Our gastroenterology business, Salix Pharmaceuticals, is one of the largest specialty pharmaceutical businesses in the world and has licensed, developed and marketed innovative products for the treatment of gastrointestinal diseases for more than 30 years. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.
Investor Contact:
Media Contact:
Garen Sarafian
Katie Savastano
ir@bauschhealth.com
corporate.communications@bauschhealth.com
877-281-6642 (toll-free)
908-569-3692
SOURCE: Bausch Health Companies Inc.
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
39 minutes ago
- Business Wire
FUN Investors Have Opportunity to Join Six Flags Entertainment Corporation Fraud Investigation With the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Six Flags Entertainment Corporation ('Six Flags' or 'the Company') (NYSE: FUN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Six Flags announced its Q2 2025 financial results on August 6, 2025. The Company swung from a profit to a $100 million dollar loss for the quarter, and cut its full year guidance. The Company blamed bad weather for the downturn but also indicated lower sales of season passes contributed to poor results. Finally, the Company's CEO will step down at the end of the year. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Business Insider
an hour ago
- Business Insider
BABA vs. AMZN: Which ‘Mega-Cap' Cloud Stock Has More Upside, According to Wall Street Analysts?
Mega-cap stocks are those with a market capitalization of $200 billion or more. Most of these stocks are associated with large, well-established companies with strong track records. Due to their sheer size, mega-cap stocks are often considered safe bets during uncertain macroeconomic times. Using TipRanks' Stock Comparison Tool, we will compare Alibaba (BABA) and Amazon (AMZN) to see which mega-cap stock has more upside ahead, according to Wall Street analysts. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Alibaba (NYSE:BABA) Stock Alibaba is China's largest e-commerce and cloud-services company, running platforms such as Taobao, Tmall, and AliCloud. The stock has surged more than 45% this year, fueled by AI-driven cloud demand and strong momentum in instant delivery services. Recently, Alibaba has ramped up efforts in its core e-commerce business. Taobao expanded its one-hour delivery service to 50 cities, hitting over 40 million daily orders during peak campaigns. The company launched a ¥10 billion ($1.4 billion) subsidy plan to compete with and Meituan in the fast-delivery space. In addition, Alibaba merged its food delivery unit, and travel services, Fliggy, into Taobao and Tmall to strengthen its retail ecosystem. Looking ahead, the company is set to report its Q1 FY26 earnings soon. Wall Street expects Alibaba to report earnings of $2.16 per share for Q1, down 6% from the year-ago quarter. The decline could be due to the company's heavy investment in logistics and delivery. Meanwhile, analysts project Q1 revenues at $35.49 billion, up 6% year-over-year. Is Alibaba Stock a Good Buy Right Now? Mizuho's Top analyst, Wei Fang, maintained an Outperform rating but trimmed the price target from $160 to $149, citing concerns about rising competition and lower near-term profitability. According to him, rising competition in China's local commerce sector, especially in food delivery and instant retail, is beginning to hurt the company's bottom line. Overall, Wall Street has a Strong Buy consensus rating on Alibaba stock based on 13 Buys and one Hold. The average Alibaba price target of $150.09 implies about 23.78% upside potential from current levels. Amazon Stock (NASDAQ:AMZN) Amazon, the global e-commerce and cloud leader, delivered better-than-expected Q2 2025 earnings. The stock has surged about 5% so far this year, driven by strength in its cloud unit, Amazon Web Services (AWS). The company is making continuous efforts to boost spending on AI infrastructure to drive long-term growth. At the same time, Amazon is doubling down on its grocery business. It recently expanded its 'Amazon Fresh' store rollout in the U.S. and is testing faster same-day grocery delivery to strengthen its retail footprint. This move is designed to increase customer loyalty and complement its Prime ecosystem. What Is the Price Target for Amazon Stock? In response to Amazon's latest grocery push, Morgan Stanley analyst Brian Nowak highlighted that expanding the grocery selection on should help the company cut delivery costs while lowering the minimum basket size. He noted that this move is part of Amazon's broader effort to capture a larger share of the $1.5 trillion offline grocery market. Based on 44 Buys and one Hold recommendation, Amazon stock earns a Strong Buy consensus rating on TipRanks. The average AMZN stock price target of $265.22 implies 14.8% upside potential from current levels. Conclusion Wall Street remains bullish on both Alibaba and Amazon stocks. However, analysts see greater upside potential in Alibaba. The Chinese giant is betting big on instant commerce and subsidies to defend market share. Meanwhile, Amazon is expanding its grocery and AI bets to drive long-term growth. While its upside may be smaller than Alibaba's, Amazon's stable growth and strong cash flow continue to earn Wall Street's confidence.
Yahoo
2 hours ago
- Yahoo
Taiwan Semiconductor Manufacturing (TSM) Announces Net Revenue for July 2025
Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) is one of the best stocks to invest in for beginners. On August 8, Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) announced its net revenue for July 2025. A close-up of a complex network of integrated circuits used in logic semiconductors. Management reported that revenue for July on a consolidated basis was around NT$323.17 billion, reflecting a growth of 22.5% compared to June 2025 and an increase of 25.8% compared to July 2024. Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) also reported that revenue for January through July 2025 totaled NT$2,096.21 billion, a growth of 37.6% compared to the same period last year. Taiwan Semiconductor Manufacturing Company Limited (NYSE:TSM) is the largest contract semiconductor manufacturer in the world. Some of its prominent customers include semiconductor companies that outsource all or part of their chip production, including Advanced Micro Devices, Nvidia, Broadcom, and more. While we acknowledge the potential of TSM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
